Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

 April 23, 2026

FDA

The U.S.

RegulatoryGene TherapyRead full story

Post navigation

CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage →
← FDA approves Regeneron’s hearing loss gene therapy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com